Title:
GLYCINE COMPOUND
Document Type and Number:
WIPO Patent Application WO/2011/034078
Kind Code:
A1
Abstract:
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease.
As the results of intensive studies on compounds having VAP-1 inhibitory activity, it was discovered that the aforesaid compound or a salt thereof shows an excellent VAP-1 inhibitory activity and, therefore, is useful in preventing and/or treating a VAP-1 associated disease, in particular, diabetic nephropathy or diabetic macular edema. The present invention has been thus completed. Also disclosed is a medicinal composition, in particular a medicinal composition for preventing and/or treating a VAP-1 associated disease, which comprises the aforesaid compound or a salt thereof and an excipient.
Inventors:
YOSHIHARA KOUSEI (JP)
SUZUKI DAISUKE (JP)
YAMAKI SUSUMU (JP)
KOGA YUJI (JP)
SEKI NORIO (JP)
FUJIYASU JIRO (JP)
NEYA MASAHIRO (JP)
SUZUKI DAISUKE (JP)
YAMAKI SUSUMU (JP)
KOGA YUJI (JP)
SEKI NORIO (JP)
FUJIYASU JIRO (JP)
NEYA MASAHIRO (JP)
Application Number:
PCT/JP2010/065918
Publication Date:
March 24, 2011
Filing Date:
September 15, 2010
Export Citation:
Assignee:
ASTELLAS PHARMA INC (JP)
YOSHIHARA KOUSEI (JP)
SUZUKI DAISUKE (JP)
YAMAKI SUSUMU (JP)
KOGA YUJI (JP)
SEKI NORIO (JP)
FUJIYASU JIRO (JP)
NEYA MASAHIRO (JP)
YOSHIHARA KOUSEI (JP)
SUZUKI DAISUKE (JP)
YAMAKI SUSUMU (JP)
KOGA YUJI (JP)
SEKI NORIO (JP)
FUJIYASU JIRO (JP)
NEYA MASAHIRO (JP)
International Classes:
C07C237/04; A61K31/165; A61K31/166; A61K31/167; A61K31/17; A61K31/18; A61K31/216; A61K31/27; A61K31/277; A61K31/351; A61K31/357; A61K31/40; A61K31/4035; A61K31/4402; A61K31/4406; A61K31/4418; A61K31/4439; A61K31/451; A61K31/454; A61K31/4545; A61K31/472; A61K31/495; A61K31/496; A61K31/505; A61K31/506; A61K31/5375; A61K31/5377; A61K31/54; A61K31/541; A61K31/55; A61K31/551; A61K31/553; C07C237/06; C07C237/08; C07C237/10; C07C237/12; C07C237/42; C07C255/60; C07C271/28; C07C275/40; C07C311/08; C07C311/21; C07C311/46; C07C317/40; C07D207/09; C07D207/12; C07D207/14; C07D207/26; C07D209/44; C07D211/46; C07D211/58; C07D211/60; C07D211/62; C07D213/40; C07D213/61; C07D213/65; C07D213/74; C07D213/75; C07D213/81; C07D213/82; C07D217/26; C07D223/12; C07D239/34; C07D239/42; C07D243/08; C07D265/30; C07D267/10; C07D295/12; C07D295/14; C07D295/18; C07D295/20; C07D295/22; C07D309/04; C07D309/14; C07D319/18; C07D401/04; C07D401/06; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D403/14; C07D405/12; C07D407/14; C07D413/04; C07D413/12; C07D417/04; C07D471/04; C07D487/04; C07D513/04; A61P1/00; A61P1/02; A61P1/16; A61P3/04; A61P3/10; A61P9/00; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/06; A61P19/02; A61P21/00; A61P25/00; A61P25/02; A61P25/28; A61P27/02; A61P29/00; A61P37/02; A61P37/08; A61P43/00
Domestic Patent References:
| WO2007018319A1 | 2007-02-15 | |||
| WO1993023023A1 | 1993-11-25 | |||
| WO2002002090A2 | 2002-01-10 | |||
| WO2002002541A2 | 2002-01-10 | |||
| WO2002038152A1 | 2002-05-16 | |||
| WO2002038153A1 | 2002-05-16 | |||
| WO2005082343A2 | 2005-09-09 | |||
| WO2009055002A1 | 2009-04-30 | |||
| WO2004067521A1 | 2004-08-12 |
Foreign References:
| JP2007500707A | 2007-01-18 | |||
| JP2002080439A | 2002-03-19 | |||
| JP2000178243A | 2000-06-27 | |||
| JPS61239891A | 1986-10-25 | |||
| US4888283A | 1989-12-19 | |||
| US20020173521A1 | 2002-11-21 |
Other References:
PURANDARE A V, ET AL.: "Pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 15, 28 June 2008 (2008-06-28), pages 4438 - 4441, XP023521570
J NEURAL TRANSM, vol. 114, 2007, pages 747 - 749
DIABETOLOGIA, vol. 42, 1999, pages 233 - 237
DIABETIC MEDICINE, vol. 16, 1999, pages 514 - 521
DIABETOLOGIA, vol. 40, 1997, pages 1243 - 1250
J NEURAL TRANSM, vol. 114, 2007, pages 841 - 843
PROG. MED., vol. 5, 1985, pages 2157 - 2161
"Drug Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
P. G. M. WUTS AND T. W. GREENE,: "Greene's Protective Groups in Organic Synthesis(4" Ed.,)", 2006, P. G. M. WUTS AND T. W. GREENE
SYNTHESIS, vol. 4, 2006, pages 629 - 632
S. R. SANDLER; W. KARO: "Organic Functional Group Preparations, 2nd edition,", vol. 1, 1991, ACADEMIC PRESS INC.
MARUZEN: "Courses in Experimental Chemistry(5th edition)", vol. 14, 2005, MARUZEN
J NEURAL TRANSM, vol. 114, 2007, pages 747 - 749
DIABETOLOGIA, vol. 42, 1999, pages 233 - 237
DIABETIC MEDICINE, vol. 16, 1999, pages 514 - 521
DIABETOLOGIA, vol. 40, 1997, pages 1243 - 1250
J NEURAL TRANSM, vol. 114, 2007, pages 841 - 843
PROG. MED., vol. 5, 1985, pages 2157 - 2161
"Drug Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
P. G. M. WUTS AND T. W. GREENE,: "Greene's Protective Groups in Organic Synthesis(4" Ed.,)", 2006, P. G. M. WUTS AND T. W. GREENE
SYNTHESIS, vol. 4, 2006, pages 629 - 632
S. R. SANDLER; W. KARO: "Organic Functional Group Preparations, 2nd edition,", vol. 1, 1991, ACADEMIC PRESS INC.
MARUZEN: "Courses in Experimental Chemistry(5th edition)", vol. 14, 2005, MARUZEN
Attorney, Agent or Firm:
MORITA, Hiroshi et al. (JP)
Morita 拓 (JP)
Morita 拓 (JP)
Download PDF: